CXCL8 and ulcerative colitis: Furthermore in the treatment of steroid resistant-ulcerative colitis with CsA, it was postulated that the therapeutic benefit may in part result from reduced capacity of neutrophils to generate ROS, undergo chemotaxis or produce pro-inflammatory cytokines (IL-8) following exposure to CsA [65].